McGill et al v. AstraZeneca Pharmaceuticals LP et al

Filing 12

ORDER addressing discovery and stay requests brought at July 17, 2017 status conference. Signed by Judge David R. Herndon on 7/18/2017. (ceh)

IN THE UNITED STATES DISTRICT COURT
FOR THE SOUTHERN DISTRICT OF ILLINOIS
IRMA COLEMAN, et al.,
Plaintiffs,
-vs-

Case No. 17-cv-130-DRH

ASTRAZENECA PHARMACEUTICALS, LP, et al.,
Defendants.
______________________________________________________________________________
JOHN ROSENSTEEL, et al.,
Plaintiffs,
-vs-

Case No. 17-cv-131-DRH

ASTRAZENECA PHARMACEUTICALS, LP, et al.,
Defendants.
______________________________________________________________________________
KENNETH LLOYD DRAVLAND, JR.
Plaintiff,
-vs-

Case No. 17-cv-133-DRH

ASTRAZENECA PHARMACEUTICALS, LP, et al.,
Defendants.
______________________________________________________________________________
ORLANDO MCGILL, et al.,
Plaintiffs,
-vs-

Case No. 17-cv-1461-DRH

ASTRAZENECA PHARMACEUTICALS, LP, et al.,
Page 1 of 6

Defendants.
______________________________________________________________________________
MARSHA RICHARDS
Plaintiff,
-vs-

Case No. 17-cv-609-DRH

PFIZER, INC., et al.,
Defendants.
______________________________________________________________________________
PATRICIA RICHARDSON
Plaintiff,
-vs-

Case No. 17-cv-406-DRH

ASTRAZENECA PHARMACEUTICALS, LP, et al.,
Defendants.
______________________________________________________________________________
TERRY WINTERS
Plaintiff,
-vs-

Case No. 17-cv-535-DRH

ASTRAZENECA PHARMACEUTICALS, LP, et al.,
Defendants.
______________________________________________________________________________
ORDER ADDRESSING DISCOVERY AND STAY REQUESTS BROUGHT AT
JULY 17th, 2017 STATUS CONFERENCE
A status conference was held July 17, 2017, at which the parties reported
on the progress of a number of aspects of this litigation.

Throughout the
Page 2 of 6

conference, it was clear the primary focus of the parties’ revolved around the
effect the approaching hearing of the Judicial Panel on Multidistrict Litigation
(“JPML”) will have if formation of a Multi-District Litigation (“MDL”) is
established. The JPML hearing is near and will be held on July 27, 2017. This
hearing

represents a

“do-over”

of plaintiffs’

previous

attempt to

attain

consolidation of the various complaints filed around the country involving the
defendants in the cases in this District as well as others.

The essence of the

parties’ diverging positions is that plaintiffs want to continue full throttle in
progressing this litigation in the event the JPML once again rejects consolidation,
while the defendants want to delay some, but not all, aspects of the litigation as
they argue against the risk of “inconsistent rulings.” Defendants point out that the
litigation, in this District and in New Jersey, continues to progress unimpeded in
areas where there isn’t such a risk.
I. Discovery Requests
One central area of contention displayed at the status conference, is in the
arena of the discovery of electronic storage of information (“ESI”). The parties
apparently have been meeting and conferring on the subject of search terms or
predictive coding, one or the other, or both, for some time. Plaintiffs feel it is time
for a deadline, which they propose be Friday, July 21st, for the parties to either
say we agree or we don’t agree, in which case briefing will be submitted to the
Court.
a. Search Terms and/or Predictive Coding
Search terms or predictive coding, whichever method is used, can be
extremely important in the course of producing ESI. Often, there is great debate
over whether these methods are helpful and bring about efficiencies or whether,
for the task at hand, create more burdens, consequently being more costly and
not very helpful overall.

Accordingly, it is important for the parties to talk

initially, present their positions to one another, and if they cannot agree, to then
present their positions in some detail to the judge for a decision.

It is also

important for this course to take place early in the process as the mining of the
Page 3 of 6

ESI gets started. This avoids having to repeat runs of the computer to go back
over data that was already searched. Thus far, defendant AstraZeneca 1 says as
for its production, they have not needed search terms - producing that which is
obvious. Per AstraZeneca, the more difficult ESI searches are not in the offing for
another few months, after the JPML hearing. Plaintiffs argue however, that there
has been nothing but “talking about talking” and it’s time to put something down
on paper so everyone knows what their guidance is as they fear there might not be
an MDL consolidation at all. Hence, plaintiffs desire for a July 21st deadline to
make a decision.
b. Privilege Log Protocol
Similarly, plaintiffs believe the parties should either submit a joint Privilege
Log Protocol to the Court by Friday, July 21st, or agree to disagree and brief it for
the Court. The arguments are very similar regarding this issue as above, and it
too, is a very preliminary matter. As documents are gathered, some may involve
conversations or simply instructions or advice, that constitute privileged
communications that should not be revealed to anyone.

Defendants have to

employ reviewers to check those things and parties usually arrive at a protocol for
how all of that is to be handled. Defendants here argue that this is too soon to
worry about in advance of the JPML hearing and there will be time after to work
this out. Plaintiffs argue that once again, there is just “talking about talking” and
if a MDL consolidation is rejected again, the parties here are well behind the
margin of error in delaying a foundational action that will cause the holdup of so
much of the ESI discovery.
II. Partial Stay
Finally, and really part and parcel to the above described disputes,
defendant AstraZeneca orally moves the Court to impose a partial stay on the
cases. While not specifically defined, the two examples above serve as a guide for
the kinds of activities AstraZeneca would have the Court hold in abeyance. The
1

For all purposes of this Order, the term “AstraZeneca” encompasses defendant AstraZeneca
Pharmaceuticals LP and defendant AstraZeneca LP.

Page 4 of 6

Court denies the stay simply because it would be too hard to define its contours
and because the Court prefers to handle the matters on an issue by issue basis.
The Court finds that it can determine for itself which issue calls out for the Court
to withhold a decision and which it should not. As it relates to the request for a
stay and the two requests discussed above, it is appropriate to describe the
Court’s philosophy regarding a stay in this matter with a decision of the JPML
pending.
III. Analysis of Court’s Philosophy Regarding Staying the Matter in Light or
Pending JPML Decision
One must first recall that the cases that are the subject of this ruling were
filed after the JPML had rejected the initial requests for consolidation and left the
parties and the undersigned to understand that each of these cases would have to
be handled in however many districts were represented by the individual cases.
Therefore, when the cases over which the undersigned is presiding were filed, the
case management presumption was that the standard protocol would be followed
- which was to handle them as expeditiously as possible and to move them
through the docket. The oral motion for partial stay was the first motion to stay
received in these cases.
The Court now finds itself at a point in the litigation where it is ten days
from a hearing where the JPML may grant a petition to consolidate even though
doing so will be contrary to the rationale of its prior decision, as most of the
defendants are now agreeing to, or at least not opposing, consolidation.
Alternatively, the JPML may once again decline the request, likely for the very
same reasons it did so before. If the petition is granted, it is likely to go to the
honorable Judge Cecchi in New Jersey, but certainly nothing in the JPML’s
judicial choice is a sure thing. So, as the Court is trying to make decisions in
these matters, the pendency of the JPML ruling becomes less of a factor than
usual.
The JPML is to hear the matter of the plaintiffs’ petitions for consolidation
very soon on July 27th. The Court believes from past practice that the panel will
Page 5 of 6

meet to decide either immediately after the conclusion of the arguments that day
or the next, or both. If there is no consolidation, this judge will know promptly.
Phone calls to the judges in the various consolidated litigations will take place
over the ensuing days and the orders will be published within a week of the
decision of the panel.

Consequently, by August 3rd or 4th, less than three

calendar weeks from today, the public will know the result for those matters
where consolidation was granted. So, it will be a mere 11 to 17 days to know the
result of the panel’s decision. Despite the compelling reasons cited by plaintiffs
for pressing ahead quickly, the more compelling reasons of avoiding conflicting
rulings, or more likely to avoid entering orders that would then be scrapped only
to start all over again, wins out. Thus, while the Court denies a stay, it will not
set a quick Friday, July 21st, deadline for the above discovery requests, as a
ruling from the JPML will be here soon.
Additionally, the Court did make one ruling from the bench, and it is
confirmed here, which is that the defendants are granted an additional thirty
days under the scheduling order, to name additional parties.
In the event the panel does reject consolidation, the next status conference
will be held August 31, 2017 at 1:30 P.M.

IT IS SO ORDERED.
DATED: July 18, 2017

Digitally signed by
Judge David R. Herndon
Date: 2017.07.18
11:34:40 -05'00'
UNITED STATES DISTRICT JUDGE

Page 6 of 6